Inicio › Cáncer de ovario › Carolina del Norte › Durham
Ensayos clínicos de Cáncer de ovario en Durham, NC
27 estudios para Cáncer de ovario buscan participantes en centros de Durham y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
The Vanguard Study: Testing a New Way to Screen for Cancer
ReclutandoSe aceptan voluntarios sanos
- Durham VA Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · A 10 mi de distancia
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
ReclutandoFase 2/3
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · A 10 mi de distancia
- University of North Carolina-Hillsborough Campus, Hillsborough · A 13 mi de distancia
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
ReclutandoFase 2
- Duke University Medical Center, Durham
A Study of PHST001 in Advanced Solid Tumors
ReclutandoFase 1
- Duke Cancer Institute, Durham
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
ReclutandoFase 1/2
- Duke University, Durham
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
ReclutandoFase 2
- University of North Carolina Medical Center /ID# 275307, Chapel Hill · A 10 mi de distancia
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
ReclutandoFase 2
- Site 0259 - Duke Cancer Center, Durham
DESTINY-PANTUMOUR04
ReclutandoEstudio observacional
- Research Site, Durham
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
ReclutandoFase 3
- Duke Cancer Institute, Durham
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
ReclutandoFase 1
- Duke University Medical Center, Durham
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
ReclutandoFase 3
- Duke Cancer Center ( Site 0012), Durham
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
ReclutandoEstudio observacional
- UNC- Chapel Hill, Chapel Hill · A 10 mi de distancia
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
ReclutandoFase 3
- Duke, Durham
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Reclutando
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · A 10 mi de distancia
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
ReclutandoFase 3
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · A 10 mi de distancia
CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
ReclutandoFase 1/2
- Duke University, Durham
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
ReclutandoFase 3
- UNC Hospital, Chapel Hill · A 10 mi de distancia
Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
ReclutandoFase 1
- Lineberger Comprehensive Cancer Center, Chapel Hill · A 10 mi de distancia
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
ReclutandoFase 3
- Duke Cancer Center, Durham
REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
Reclutando
- Duke Cancer Center, Durham
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
ReclutandoFase 1
- Site 0259, Durham
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
Reclutando
- Duke University Hospital, Durham
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
ReclutandoFase 1/2
- Duke Cancer Center/ DUMC, Durham
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
ReclutandoFase 1
- Duke Cancer Institute, Durham
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
ReclutandoFase 2
- Duke Cancer Center, Durham
Multimedia Aid for Genetic Testing in Gynecologic Oncology
Reclutando
- Univeristy of North Carolina at Chapel Hill, Chapel Hill · A 10 mi de distancia
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
ReclutandoEstudio observacional
- Massive Bio SYNERGY-AI site, Chapel Hill · A 10 mi de distancia
Más información sobre Cáncer de ovario en MedlinePlus
Ensayos de Cáncer de ovario en otras ciudades
- Houston, TX89 estudios
- New York City, NY69 estudios
- Boston, MA61 estudios
- Los Angeles, CA50 estudios
- Nashville, TN49 estudios
- Arlington, VA46 estudios
- Philadelphia, PA44 estudios
- Columbus, OH39 estudios
- St. Louis, MO38 estudios
- Chicago, IL36 estudios
- San Antonio, TX31 estudios
- Cleveland, OH30 estudios
Otros estudios en Durham
- Cáncer de seno64 estudios
- Cáncer (todos los tipos)58 estudios
- Cáncer de pulmón de células no pequeñas39 estudios
- Mieloma múltiple37 estudios
- Leucemia mielógena aguda33 estudios
- Cáncer metastásico33 estudios
- Cáncer de próstata32 estudios
- Cáncer de pulmón32 estudios
- Cáncer del colon y del recto28 estudios
- Leucemia linfocítica crónica27 estudios
- Fallo cardíaco26 estudios
- Cáncer de páncreas24 estudios
De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.